• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session

    7/7/22 12:02:17 PM ET
    $ACCD
    $ACRX
    $ALNA
    $AREB
    Business Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACCD alert in real time by email

    Gainers

    • United Maritime Corporation (NASDAQ:USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp.
    • American Rebel Holdings, Inc. (NASDAQ:AREB) gained 85% to $1.4150. American Rebel Holdings agreed to acquire Utah-based Champion Safe Company and its ancillary companies, in a transaction valued at $9.9 million.
    • Grove Collaborative Holdings, Inc. (NYSE:GROV) shares jumped 66.3% to $6.65 amid news the company's products will now be available in Kohl's (NYSE:KSS), Midwest-based Meijer and also Giant Eagle.
    • Kiromic BioPharma, Inc. (NASDAQ:KRBP) surged 41% to $0.54. Kiromic BioPharma completed the construction of its expanded current good manufacturing practice manufacturing facility in Houston.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) gained 39% to $6.31.
    • Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) jumped 30.6% to $0.2311 after declining over 8% on Wednesday. Allena Pharmaceuticals recently announced rescheduling of special meeting to approve reverse stock split.
    • Immuron Limited (NASDAQ:IMRN) gained 22% to $2.60. Immuron received European Patent notification on drug composition to treat clostridioides difficile associated disease.
    • OceanPal Inc. (NASDAQ:OP) jumped 21.3% to $0.5458. OceanPal recently announced time charter contract for m/v Calipso.
    • Cryptyde, Inc. (NASDAQ:TYDE) rose 19% to $1.44. Cryptyde recently disclosed a corporate roadmap for the remainder of 2022 into 2023.
    • Target Hospitality Corp. (NASDAQ:TH) gained 16.7% to $5.78.
    • SIGNA Sports United N.V. (NYSE:SSU) jumped 16.4% to $6.40.
    • Bed Bath & Beyond Inc. (NASDAQ:BBBY) rose 16.1% to $5.19 after several SEC filings showed recent insider buying.
    • Longeveron Inc. (NASDAQ:LGVN) shares gained 15.9% to $7.06. Longeveron said an abstract regarding the Lomecel-B Phase 2a trial in Alzheimer's Disease has been accepted for presentation at the Alzheimer's Association International Conference.
    • Visionary Education Technology Holdings Group Inc. (NASDAQ:VEDU) gained 15.9% to $1.7173.
    • Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) gained 13.5% to $3.10. Verrica Pharmaceuticals recently priced its underwritten public offering of 12,000,000 shares at $2.10 per share.
    • Accolade, Inc. (NASDAQ:ACCD) gained 13.2% to $10.47.
    • Crescent Point Energy Corp. (NYSE:CPG) surged 13.1% to $7.24 after the company announced an increase to its quarterly dividend and updated FY22 guidance.
    • iSpecimen Inc. (NASDAQ:ISPC) jumped 13.1% to $2.68. iSpecimen added new global biospecimen suppliers to proprietary marketplace platform for researchers to leverage.
    • Veru Inc. (NASDAQ:VERU) rose 12.9% to $14.70. Veru shares gained 13% on Wednesday after the company announced the publication of the results from a Phase 3 COVID-19 study evaluating the efficacy and safety of oral sabizabulin for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for ARDS and death in The New England Journal of Medicine Evidence.
    • Palisade Bio, Inc. (NASDAQ:PALI) gained 12.8% to $0.4821.
    • Daqo New Energy Corp. (NYSE:DQ) jumped 12% to $74.99.
    • JinkoSolar Holding Co., Ltd. (NYSE:JKS) jumped 11.3% to $72.93. JinkoSolar recently announced up to $200 million share buyback program.
    • NIO Inc. (NYSE:NIO) gained 9.3% to $22.76, a day after its Nio Power Day 2022, where it announced a 500-kilowatt ultra-fast charging pile and offered a glimpse into its third-generation battery swap station.
    • AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) gained 8.7% to $0.2801 after gaining around 4% on Wednesday.
    • ON Semiconductor Corporation (NASDAQ:ON) jumped 8.4% to $51.61 in sympathy with Samsung, which reported a 21% increase in quarterly revenue.
    • MIND Technology, Inc. (NASDAQ:MIND) rose 7.8% to $0.90 after the company announced that it received orders for sonar and source controller systems totaling approximately $7.7 million.
    • BioRestorative Therapies, Inc. (NASDAQ:BRTX) gained 7.8% to $3.33. BioRestorative Therapies recently enrolled first patient in the phase 2 clinical study of its lead drug BRTX-100 in chronic lumbar disc disease (cLDD).
    • GameStop Corp. (NYSE:GME) rose 7% to $125.61 after the company announced a stock split.
    • Alibaba Group Holding Limited (NYSE:BABA) gained 4.8% to $124.85. China's cyberspace regulator informed that rules requiring data exports to undergo security reviews would be effective from September 1, Reuters reported.


    Losers

    • Integrated Media Technology Limited (NASDAQ:IMTE) shares tumbled 59.8% to $2.10.
    • DiaMedica Therapeutics Inc. (NASDAQ:DMAC) shares dipped 37.7% to $1.2595 after the company announced the FDA has placed a clinical hold on its Phase 2/3 ReMEDy2 trial for DM199.
    • CytomX Therapeutics, Inc. (NASDAQ:CTMX) fell 29.4% to $1.39 after the company reported Phase 2 results for praluzatamab ravtansine in breast cancer. Piper Sandler and Mizuho downgraded the stock also.
    • Avalo Therapeutics, Inc. (NASDAQ:AVTX) dipped 23.7% to $0.4155. Avalo Therapeutics announced one-for-twelve reverse stock split.
    • Waitr Holdings Inc. (NASDAQ:WTRH) shares fell 22.3% to $0.2062 after jumping 73% on Wednesday.
    • USANA Health Sciences, Inc. (NYSE:USNA) fell 16% to $64.29 after the company reported preliminary second-quarter results and updated its FY22 outlook. The company said it expects net sales of $1.015 billion- $1.065 billion, versus prior guidance of $1.1 billion - $1.2 billion. It also sees EPS of $3.85 - $4.45, compared to prior guidance of $5.00 - $5.70.
    • BioVie Inc. (NASDAQ:BIVI) fell 13.9% to $1.67.
    • Enjoy Technology, Inc. (NASDAQ:ENJY) shares fell 12.8% to $0.3655 after jumping 35% on Wednesday.
    • Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) dipped 9.2% to $13.89. Intercept Pharmaceuticals announced positive topline results from a new interim analysis of its ongoing pivotal Phase 3 REGENERATE trial of OCA in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH).
    • Revelation Biosciences, Inc. (NASDAQ:REVB) fell 9.1% to $1.0903 after jumping 44% on Wednesday.
    • Helen of Troy Limited (NASDAQ:HELE) dropped 8.8% to $154.97 after the company reported worse-than-expected Q1 EPS results and cut FY23 adjusted EPS and sales guidance below estimates.
    • The Duckhorn Portfolio, Inc. (NASDAQ:NAPA) fell 8.1% to $19.06 after the company reported a secondary offering of 5,000,000 shares of common stock.
    • IperionX Limited (NASDAQ:IPX) fell 8% to $4.4999.
    • Revlon, Inc. (NYSE:REV) dropped 7.9% to $5.84 on continued post-bankruptcy volatility.
    • IN8bio, Inc. (NASDAQ:INAB) dropped 7.6% to $2.18.
    • Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) fell 7.2% to $0.8350. Titan Pharmaceuticals shares jumped 49% on Wednesday after the company announced FDA clearance of its IND application for nalmefene implant.
    • Art's-Way Manufacturing Co., Inc. (NASDAQ:ARTW) fell 6.7% to $2.22. Art's-Way Manufacturing recently posted Q2 EPS of $0.04.
    Get the next $ACCD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACCD
    $ACRX
    $ALNA
    $AREB

    CompanyDatePrice TargetRatingAnalyst
    Alibaba Group Holding Limited
    $BABA
    2/18/2026Buy → Hold
    Erste Group
    ON Semiconductor Corporation
    $ON
    2/12/2026$75.00Equal Weight
    Barclays
    ON Semiconductor Corporation
    $ON
    2/10/2026Buy → Hold
    The Benchmark Company
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    ON Semiconductor Corporation
    $ON
    1/22/2026$62.00Underperform → Neutral
    BNP Paribas Exane
    Alibaba Group Holding Limited
    $BABA
    1/21/2026$190.00Neutral → Buy
    Arete
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    NIO Inc.
    $NIO
    1/15/2026$6.10Neutral → Outperform
    Macquarie
    More analyst ratings

    $ACCD
    $ACRX
    $ALNA
    $AREB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

    Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 subjects supports differentiated, colon-targeted PDE4 approach Translational analyses confirm local suppression of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling in colon tissue with minimal peripheral immune modulation Data presented at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, Sweden Carlsbad, CA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmac

    2/23/26 8:40:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    American Rebel Holdings, Inc. (NASDAQ: AREB) announces a partnership with Jefferson Distributing to launch American Rebel Light Beer in West Virginia's Eastern Panhandle, expanding distribution across Jefferson, Morgan and Berkeley Counties

    Top-tier Anheuser-Busch network distribution partner Jefferson Distributing (WV) adds critical "footprint fill-in" coverage as American Rebel continues rapid national expansion with sustained execution of its Distribution-First strategy Nashville, TN, Feb. 23, 2026 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ:AREB) ("American Rebel" or the "Company"), America's Patriotic Brand™ and maker of American Rebel Light Beer, announced that it has executed a distribution agreement with Jefferson Distributing Company, a wholesaler founded in 1960 and based in Charles Town, West Virginia. American Rebel is America's Patriotic, God-Fearing, Constitution-Loving, National Anthem Singing, S

    2/23/26 8:30:00 AM ET
    $AREB
    Plastic Products
    Industrials

    Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

    WEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the TD Cowen 46th Annual Healthcare Conference in Boston. TD Cowen 46th Annual Health Care Conference, March 2-4, 2026Event details:Date: Monday, March 2, 2026Time: 10:30am ETLocation: Boston, Massachusetts Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors/P

    2/23/26 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $ACRX
    $ALNA
    $AREB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alibaba downgraded by Erste Group

    Erste Group downgraded Alibaba from Buy to Hold

    2/18/26 9:41:39 AM ET
    $BABA
    Real Estate

    Barclays initiated coverage on onsemi with a new price target

    Barclays initiated coverage of onsemi with a rating of Equal Weight and set a new price target of $75.00

    2/12/26 9:42:14 AM ET
    $ON
    Semiconductors
    Technology

    onsemi downgraded by The Benchmark Company

    The Benchmark Company downgraded onsemi from Buy to Hold

    2/10/26 7:17:53 AM ET
    $ON
    Semiconductors
    Technology

    $ACCD
    $ACRX
    $ALNA
    $AREB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group President, PSG Keeton Simon sold $3,505,699 worth of Common (48,860 units at $71.75), decreasing direct ownership by 20% to 198,995 units (SEC Form 4)

    4 - ON SEMICONDUCTOR CORP (0001097864) (Issuer)

    2/18/26 5:55:42 PM ET
    $ON
    Semiconductors
    Technology

    Chief Medical Officer Jones Mitchell Lawrence converted options into 8,000 shares and sold $3,481 worth of shares (1,989 units at $1.75), increasing direct ownership by 83% to 13,263 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:10:12 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO, CFO Finley John David converted options into 13,333 shares and sold $6,818 worth of shares (3,896 units at $1.75), increasing direct ownership by 53% to 27,353 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:07:40 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $ACRX
    $ALNA
    $AREB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

    Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer

    7/21/23 4:54:32 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-8) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 02/24/2022. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    2/25/22 4:36:46 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $ACRX
    $ALNA
    $AREB
    SEC Filings

    View All

    American Rebel Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AMERICAN REBEL HOLDINGS INC (0001648087) (Filer)

    2/19/26 5:05:53 PM ET
    $AREB
    Plastic Products
    Industrials

    iSpecimen Inc. filed SEC Form 8-K: Other Events

    8-K - iSpecimen Inc. (0001558569) (Filer)

    2/18/26 4:30:19 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form PRER14C filed by American Rebel Holdings Inc.

    PRER14C - AMERICAN REBEL HOLDINGS INC (0001648087) (Filer)

    2/17/26 9:37:20 PM ET
    $AREB
    Plastic Products
    Industrials

    $ACCD
    $ACRX
    $ALNA
    $AREB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cheng Lawrence bought $114,368 worth of shares (5,000 units at $22.87) (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/26/26 9:06:47 AM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    President, CEO and Chairman Cohen Ryan bought $21,359,200 worth of shares (1,000,000 units at $21.36), increasing direct ownership by 3% to 38,347,842 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/22/26 4:02:03 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    Director Attal Alain bought $259,577 worth of shares (12,000 units at $21.63), increasing direct ownership by 2% to 596,464 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/21/26 6:32:09 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $ACCD
    $ACRX
    $ALNA
    $AREB
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $ACRX
    $ALNA
    $AREB
    Financials

    Live finance-specific insights

    View All

    USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026. Key Financial and Operating Results   Q4 2025   Q4 2024   FY 2025   FY 2024 Net sales $226.2   $213.6   $925.3   $854.5 Net (loss) earnings* $-1.8   $4.5   $10.8   $42.0 Diluted EPS $-0.10   $0.23   $0.58   $2.19 Adjusted diluted EPS(1) $0.60   $0.64   $1.93   $2.59 Adjusted EBITDA(2) $27.3

    2/17/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Daqo New Energy to Announce Unaudited Results for the Fourth Quarter and Fiscal Year 2025 on February 26, 2026

    SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- Daqo New Energy Corp. (NYSE:DQ) ("Daqo New Energy" or the "Company"), a leading manufacturer of high-purity polysilicon for the global solar PV industry, today announced it plans to release its unaudited financial results for fourth quarter and fiscal year ended December 31, 2025, before U.S. markets open on Thursday, February 26, 2026. The Company has scheduled a conference call to discuss the results at 8:00 AM U.S. Eastern Time on Thursday, February 26, 2026 (9:00 PM Beijing / Hong Kong time on the same day). The dial-in details for the earnings conference call are as follows: Participant dial in (U.S. toll free): +1-888-346-8982Participant interna

    2/12/26 6:00:00 AM ET
    $DQ
    Semiconductors
    Technology

    Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

    -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 first quarter ended December 31, 2025, and provided a corporate update. "The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 receptor agonists for

    2/11/26 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $ACRX
    $ALNA
    $AREB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    12/9/24 6:22:49 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by OceanPal Inc.

    SC 13D/A - OceanPal Inc. (0001869467) (Subject)

    12/2/24 4:18:52 PM ET
    $OP
    Marine Transportation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by OceanPal Inc.

    SC 13D/A - OceanPal Inc. (0001869467) (Subject)

    12/2/24 4:17:41 PM ET
    $OP
    Marine Transportation
    Consumer Discretionary